Search

Displaying results 5871 - 5880 of 10000 in total
  1. Drug

    Tigatuzumab

    go.drugbank.com/drugs/DB15101
    Investigational

    Tigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).

  2. Drug

    Rasdegafusp alfa

    go.drugbank.com/drugs/DB15185
    Investigational

    Rasdegafusp alfa is under investigation in clinical trial NCT03206047 (Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal

  3. Drug

    PR1 leukemia peptide vaccine

    go.drugbank.com/drugs/DB15276
    Investigational

    PR1 leukemia peptide vaccine is under investigation in clinical trial NCT00513578 (Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome).

    Synonyms: PR-1, L-VALINE, L-VALYL-L-LEUCYL-L-GLUTAMINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-ASPARAGINYL-L-VALYL-L-THREONYL-
  4. Drug

    Cardiopet

    go.drugbank.com/drugs/DB18913
    Investigational

    Cardiopet is under investigation in clinical trial NCT01826773 (Cardiopet as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects).

  5. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI. … It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation

  6. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

  7. Drug

    Etilamfetamine

    go.drugbank.com/drugs/DB13285
    Experimental

    However, being on the controlled drug and substance act does not necessitate that the drug is approved for sale on the market. … Etilamfetamine is also known as N-ethylamphetamine and is in the Canadian Legislation - The Controlled Drugs and Substances Act, and is a Schedule 1 controlled drug.

  8. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. … isomer as [DB00470], or in a 1:1 formulation with CBD from purified plant extract as [DB14011].

  9. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  10. Drug

    Osunprotafib

    go.drugbank.com/drugs/DB21547
    Investigational

    Osunprotafib has a monoisotopic molecular weight of 385.15 Da. … Osunprotafib is under investigation in clinical trial NCT04777994 (Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors).